Skip to content
Inciteful Med

Survivorship & Long-Term Monitoring: Life After Diagnosis

Last updated:

Life after a non-functioning pituitary adenoma (NFPA) requires long-term monitoring, including regular MRI scans to check for tumor recurrence. Survivors must also manage potential long-term effects on bone health, sleep, and memory, often with the help of targeted hormone replacement therapy.

Key Takeaways

  • • Long-term MRI surveillance is essential to catch any regrowth of a non-functioning pituitary adenoma.
  • • Recurrence risk is significantly higher if a piece of the tumor was intentionally left behind during surgery.
  • • Adjuvant radiation can effectively prevent tumor regrowth in patients with residual tumor tissue.
  • • Survivors must carefully manage hormone replacement therapies, like hydrocortisone and growth hormone, to protect long-term heart and bone health.
  • • Anxiety before annual MRIs is common and can be managed through fast result reporting and cognitive behavioral therapy.

Entering the “survivorship” phase of life with a non-functioning pituitary adenoma (NFPA) means shifting your focus from immediate treatment to long-term monitoring and wellness. Because these tumors are benign but persistent, life-long surveillance is essential to catch any regrowth early and manage the “hidden” long-term effects on your body [1][2].

Long-Term Surveillance Schedule

Your monitoring schedule depends largely on how much of the tumor was removed during surgery. The goal of this “watchful waiting” is to ensure your vision and hormones remain protected [1].

Situation First 1–2 Years Years 2–5 Year 5 and Beyond
Gross Total Resection (GTR) (Tumor completely removed) MRI at 3 or 6 months, then at 1 year [1]. Annual MRI [1]. Scans at years 7, 10, and 15 [1].
Subtotal Resection (STR) (Residual piece remains) MRI at 3 or 6 months, then annual MRI [1]. Annual MRI [1]. Indefinite annual or biennial MRI [1].

Understanding Recurrence

Recurrence—the tumor growing back—is a major part of the NFPA journey. Reported recurrence rates within the first five years range from around 12% for patients who had a complete tumor removal (Gross Total Resection), up to 66% for patients who had a large piece of the tumor intentionally left behind (Subtotal Resection) and did not receive subsequent radiation [3][4]. Knowing the extent of your surgery provides crucial context so you don’t panic at the high-end statistics.

  • Risk Factors: The biggest predictors of recurrence are whether the tumor had invaded the cavernous sinus (Knosp Grade 3 or 4) and whether a piece was left behind during surgery (STR) [4][5].
  • The Power of Radiation: For those with a residual piece, adjuvant radiation can be highly effective; one study showed a 0% recurrence rate at 10 years when radiation followed a partial removal [6].

The “Hidden” Long-Term Effects

Life after an NFPA is often about managing more than just the tumor itself. Research shows several areas that require long-term attention:

  • Bone Health: NFPA patients often have higher levels of sclerostin, a protein that can lower bone mineral density [7]. Up to 26% of survivors may experience vertebral (spine) fractures, particularly if they have untreated hormone deficiencies [8].
  • Sleep and Mood: Over 57% of survivors report poor sleep quality [9]. This is frequently linked to depression or the timing of hormone replacement medications [9].
  • Cognitive Function: Many patients experience subtle “neurocognitive failure,” such as trouble with memory or social interactions [10]. These can be side effects of the tumor’s pressure, the surgery, or even radiation [10][2].

Mortality, Hormone Replacement, and Adrenal Crisis

While NFPA is not a malignant cancer, survivors have a slightly higher risk of stroke and cardiovascular issues compared to the general population [11].

  • The GHRT Advantage: Growth Hormone Replacement Therapy (GHRT) has been shown to be a powerful tool. Not only is it safe and does not increase the risk of the tumor growing back, but it is actually associated with a reduced mortality risk and improved quality of life [12][13][14].
  • Steroid Management: If you take hydrocortisone, it is vital to keep the dose as low as safe (usually ≤\le 20 mg/day) to minimize long-term risks to your heart and bones [15][16]. Furthermore, it is vital to know how to “stress-dose” your steroids during illness or severe stress to prevent a life-threatening adrenal crisis [17].

Managing “Scanxiety”

It is normal to feel intense anxiety before your annual MRI, a phenomenon often called scanxiety [18]. Research suggests that “outcome fantasy”—obsessing over what the scan might show—increases distress [19]. To manage this, patients often find success by:

  • Requesting Fast Results: Ask your clinic for a plan to get your results within 24–48 hours [18].
  • Present-Moment Coping: Focus on the physical sensations of the current day rather than speculating on the future [19].
  • Professional Support: Cognitive Behavioral Therapy (CBT) has been proven to help survivors manage the fear of recurrence and the uncertainty of long-term monitoring [20].

Frequently Asked Questions

How often do I need an MRI after pituitary tumor surgery?
Your MRI schedule depends on how much of the tumor was removed. If the tumor was completely removed, you typically need a scan at 3 to 6 months, then annually, with spaced-out scans after five years. If a piece remains, you will likely need annual MRIs indefinitely.
What is the recurrence rate for a non-functioning pituitary adenoma?
The chance of the tumor growing back within five years ranges from about 12% if it was completely removed, up to 66% if a portion was left behind and no radiation was given. Tumors that invade the cavernous sinus or are only partially removed have a higher risk of recurrence.
Can a pituitary tumor cause long-term memory or cognitive issues?
Yes, many patients experience subtle cognitive changes, such as trouble with memory or social interactions, long after treatment. These issues can be late side effects from the tumor's pressure on the brain, the surgery itself, or radiation therapy.
Is growth hormone replacement safe after a pituitary tumor?
Yes, Growth Hormone Replacement Therapy (GHRT) is considered safe and does not increase the risk of the tumor growing back. In fact, it is associated with improved quality of life and a reduced mortality risk for survivors.
What is scanxiety and how can I manage it?
Scanxiety is the intense distress patients often feel before an annual MRI. You can help manage it by asking your clinic for a plan to get your results within 24 to 48 hours, practicing mindfulness to stay in the present moment, or seeking Cognitive Behavioral Therapy.

Questions for Your Doctor

  • • Based on my 'resection extent' (GTR vs. STR), what is my specific MRI schedule for the next five years?
  • • Since I have hypopituitarism, am I at an increased risk for bone density loss or vertebral fractures, and should I have a DEXA scan?
  • • How will we monitor the long-term side effects of my radiation treatment, specifically regarding my memory and hormone levels?
  • • Is my current hydrocortisone dose higher than 20 mg per day, and if so, can we adjust it to reduce my long-term cardiovascular risks?
  • • Am I a candidate for Growth Hormone Replacement Therapy (GHRT), and how would that impact my quality of life and overall mortality risk?
  • • What is your clinic's process for getting me my MRI results quickly to help manage my scan anxiety?

Questions for You

  • • How do I feel in the weeks leading up to my annual MRI, and do I have a 'coping plan' (like mindfulness or a support person) to manage that stress?
  • • Have I noticed any subtle memory issues, like forgetting names or losing my train of thought, that I should mention to my doctor?
  • • Is my sleep quality affecting my daily life, and have I tracked whether my energy levels fluctuate with my hormone medication timing?
  • • Do I have a 'central file' (digital or physical) where I keep all my MRI reports and blood work results for long-term tracking?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Post-surgical management of non-functioning pituitary adenoma.

    Cortet-Rudelli C, Bonneville JF, Borson-Chazot F, et al.

    Annales d'endocrinologie 2015; (76(3)):228-38.

    PMID: 26116412
  2. 2

    Clinical Concerns about Recurrence of Non-Functioning Pituitary Adenoma.

    Lee MH, Lee JH, Seol HJ, et al.

    Brain tumor research and treatment 2016; (4(1)):1-7 doi:10.14791/btrt.2016.4.1.1.

    PMID: 27195254
  3. 3

    MRI radiomics for the prediction of recurrence in patients with clinically non-functioning pituitary macroadenomas.

    Machado LF, Elias PCL, Moreira AC, et al.

    Computers in biology and medicine 2020; (124()):103966 doi:10.1016/j.compbiomed.2020.103966.

    PMID: 32860977
  4. 4

    Nomogram predictive model of post-operative recurrence in non-functioning pituitary adenoma.

    Lyu W, Fei X, Chen C, Tang Y

    Gland surgery 2021; (10(2)):807-815 doi:10.21037/gs-21-47.

    PMID: 33708562
  5. 5

    Is Positive Staining of Non-Functioning Pituitary Adenomas for Luteinizing Hormone Associated with a Poor Prognosis?

    Diri H, Ozaslan E, Kurtsoy A, et al.

    Turkish neurosurgery 2017; (27(1)):8-13 doi:10.5137/1019-5149.JTN.14889-15.1.

    PMID: 27593756
  6. 6

    Long-Term Functional and Tumor Outcomes Following Uni-Nostril Endoscopic Surgery for Non-Functioning Pituitary Adenomas: Results in 172 Patients.

    Baldia M, D'Souza WP, Girishan S, et al.

    Neurology India 2025; (73(1)):55-63 doi:10.4103/neurol-india.Neurol-India-D-23-00640.

    PMID: 40652469
  7. 7

    Low Bone Density and High Sclerostin in Non-Functioning Pituitary Adenoma.

    Pekkolay Z, Yıldırım DV, Tuzcu ŞA, et al.

    Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2023; (26(2)):101363 doi:10.1016/j.jocd.2023.03.002.

    PMID: 37002004
  8. 8

    High prevalence of morphometric vertebral fractures opportunistically detected on thoracic radiograms in patients with non-functioning pituitary adenoma.

    Frara S, Uygur MM, Bolamperti F, et al.

    Pituitary 2024; (27(4)):370-380 doi:10.1007/s11102-024-01394-z.

    PMID: 38802688
  9. 9

    Sleep quality in patients with non-functioning pituitary adenoma: impact of replacement therapies with an emphasis on the time of hydrocortisone.

    Barlas T, Yalcin MM, Avci DE, et al.

    Pituitary 2023; (26(4)):411-418 doi:10.1007/s11102-023-01328-1.

    PMID: 37261656
  10. 10

    Neurocognitive evaluation of patients with non-functioning pituitary adenoma.

    Altinbezer A, Barlas T, Aksu MH, et al.

    Pituitary 2025; (28(5)):105 doi:10.1007/s11102-025-01582-5.

    PMID: 41006692
  11. 11

    Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study.

    Oh JS, Kim HJ, Hann HJ, et al.

    Pituitary 2021; (24(1)):38-47 doi:10.1007/s11102-020-01084-6.

    PMID: 32949324
  12. 12

    Life expectancy in patients with pituitary adenoma receiving growth hormone replacement.

    Olsson DS, Trimpou P, Hallén T, et al.

    European journal of endocrinology 2017; (176(1)):67-75 doi:10.1530/EJE-16-0450.

    PMID: 27770012
  13. 13

    Healthcare cost and survival in patients with non-functioning pituitary adenoma.

    Olsson DS, Svensson M, Labori F, et al.

    European journal of endocrinology 2023; (188(6)):477-484 doi:10.1093/ejendo/lvad057.

    PMID: 37232269
  14. 14

    Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence.

    Losa M, Castellino L, Pagnano A, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(5)) doi:10.1210/clinem/dgaa089.

    PMID: 32112101
  15. 15

    Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma.

    Hammarstrand C, Ragnarsson O, Hallén T, et al.

    European journal of endocrinology 2017; (177(3)):251-256.

    PMID: 28596421
  16. 16

    Health-related quality of life in patients with non-functioning pituitary adenoma: a special focus on hydrocortisone replacement dose.

    Wild CM, Stieg M, Stalla GK, et al.

    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2020; (29(12)):3325-3331 doi:10.1007/s11136-020-02582-7.

    PMID: 32737686
  17. 17

    Cut-off values for sufficient cortisol response to low dose Short Synacthen Test after surgery for non-functioning pituitary adenoma.

    Kolnes AJ, Øystese KA, Dahlberg D, et al.

    Acta neurochirurgica 2020; (162(4)):845-852 doi:10.1007/s00701-019-04068-z.

    PMID: 31907611
  18. 18

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  19. 19

    Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

    Dunsmore VJ, Neupert SD

    Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

    PMID: 36964680
  20. 20

    A multi-site feasibility study of a stepped-care telehealth intervention for depression and anxiety in post-treatment cancer survivors at community cancer clinics (WF-30917CD).

    Danhauer SC, Brenes GA, Weaver KE, et al.

    Journal of cancer survivorship : research and practice 2025; doi:10.1007/s11764-024-01721-0.

    PMID: 39810026

This page provides educational information about survivorship and long-term monitoring for NFPA. It does not replace professional medical advice. Always consult your endocrinologist or neurosurgeon regarding your specific scan schedule and hormone management.

Stay up to date

Get notified when new research about Non-functioning pituitary adenoma is published.

No spam. Unsubscribe anytime.